Unopposed oestrogens (oral)
Choice | Drug | Dosage |
---|---|---|
1st choice | Elleste-Solo® 1mg, 2mg (estradiol) tablets | Dose: Elleste-Solo® 2mg tablets - menopausal symptoms not controlled with lower strength and osteoporosis prophylaxis (see section 6.6), 2 mg daily |
Unopposed oestrogens (transdermal)
Choice | Drug | Dosage |
---|---|---|
1st choice | Evorel® patches 50micrograms (or 25micrograms, 75micrograms, 100micrograms/24 hours) (estradiol) | Dose: Therapy should be initiated with Evorel® 50 patch; subsequently adjust according to response; dose may be reduced to Evorel® 25 patch after first month if necessary for menopausal symptoms only |
Unopposed oestrogens (gel)
Choice | Drug | Dosage |
---|---|---|
1st choice | Oestrogel® 0.06% gel | Dose: |
Prescribing Notes
- HRT preparations should be brand prescribed to aid product identification
- It is recommended that the lowest dose of HRT based on relieving menopausal symptoms should be prescribed
- Women with an early menopause (<45 years), especially if surgically induced, require the higher dose of oestrogen to control their vasomotor symptoms and for bone protection
- Mirena® is licensed for 4 years for endometrial protection during oestrogen replacement therapy (i.e. Mirena® provides the progestogen component of HRT). In practice, it is used for up to 5 years, providing the woman is not experiencing bleeding
Preparations for vaginal atrophy
See section 7.2.1